READ MORE Benicar LEGAL NEWS
Patients with sprue-like enteropathy experience chronic diarrhea, weight loss and other gastrointestinal problems, including colitis. Symptoms can reportedly take months to years to develop and may require hospitalization. Some patients may have developed sprue-like enteropathy while using Benicar but been diagnosed with celiac disease. The lawsuits consolidated under the MDL allege the Daiichi Sankyo and Forest Laboratories failed to warn users about these medical side effects.
Benicar (known generically as olmesartan) is in a class of drugs known as angiotensin II receptor blockers (ARB). According to the FDA, sprue-like enteropathy has not been linked with other ARB medications.